Меню
Идёт набор NCT06331676

Developing a Complex ex Vivo Endometrial Tissue Model to Improve Endometriosis Care

Без фазы С лечением Endometriosis

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: Tissue collection, Data collection.
Кому может быть актуально
Состояния в реестре: Endometriosis. Базовые параметры: 18 лет — 50 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Франция
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Официальное название

Developing a Complex ex Vivo Endometrial Tissue Model Based on Patient Biopsies to Assess and Optimise the Response to Current and Potential Treatments for Endometriosis

Обзор

Endometriosis is a chronic gynaecological disease characterised by the growth of endometrium outside the uterus. It affects 10% of childbearing age women. There is no cure for endometriosis. Hormonal treatments should be the first line therapy. The benefit-risk ratio of symptomatic treatment with hormone therapy varies greatly from one woman to another. The pathophysiology of endometriosis and the mechanisms of action of these treatments are still poorly understood. This may be due to the lack of an optimal experimental model for studying the disease. The aim of this project is to develop a complex ex vivo endometrial model recapitulating the organisation and properties of the human endometrium using innovative tissue bioengineering methods. This model will make it possible to develop a pre-clinical approach that predicts individual response to different types of hormonal treatment in order to optimise therapeutic choices and provide a better understanding of the effects of these treatments.

Вмешательства

  • Процедура Tissue collection
    Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling
  • Другое Data collection
    Questionnaire on menstrual health and history of hormone treatments for the research purpose

Первичные конечные точки

  • Viability of all the cells forming the complex endometrial tissue generated ex vivo by tissue bioengineering. [Срок оценки: through study completion, an average of 18 months]
Вторичные конечные точки (8)
  • Change in protein expression [Срок оценки: through study completion, an average of 18 months]
  • Change in gene expression [Срок оценки: through study completion, an average of 18 months]
  • Change in inflammation [Срок оценки: through study completion, an average of 18 months]
  • Change in histological tissue structure [Срок оценки: through study completion, an average of 18 months]
  • Change in histological tissue structure [Срок оценки: through study completion, an average of 18 months]
  • Change in tissue elasticity [Срок оценки: through study completion, an average of 18 months]
  • Change in steroid hormone physiology [Срок оценки: At baseline]
  • Steroid hormones in peritoneal fluid [Срок оценки: At baseline]

Критерии участия

Критерии включения

  • Female
  • People aged between 18 and 50
  • Person who has or has had hormonal contraceptive treatment
  • A person who has given written consent
  • Person diagnosed with a benign gynaecological pathology not affecting the endometrium and requiring hysterectomy, hysteroscopy or laparoscopy or with a diagnosis of endometriosis and requiring laparoscopy or hysterectomy
  • Person affiliated to the french social security

Критерии исключения

  • Pregnant at the time of sampling or within 3 months prior to sampling
  • Breast-feeding women
  • Women undergoing physiological menopause
  • Anyone who has received hormonal treatment with hormones other than steroids in the three months prior to sampling
  • Anyone with a non-hormonal contraceptive intrauterine device (copper coil)
  • Anyone with a personal history of cancer of the breast, ovary, endometrium or cervix
  • People with Lynch syndrome
  • Persons under legal protection (guardianship, curatorship)
  • Persons deprived of their liberty by judicial or administrative decision
  • Persons with a body mass index (BMI) of less than 18.5 or more than 30

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Нерандомизированное
Модель
Параллельные группы
Маскирование
Открытое
Основная цель
Фундаментальное исследование

Центры проведения

Франция · 2 центра
  • Hôpital Femme Mère Enfant / GHE — Bron
  • Hôpital de la Croix-Rousse / GHN — Lyon

Идентификаторы

NCT: NCT06331676 · 69HCL23_1120 · 2023-A02339-36

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗